Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $321,000.

  • Corvus Pharmaceuticals' Total Non-Current Liabilities fell 48.64% to $321,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $321,000, marking a year-over-year decrease of 48.64%. This contributed to the annual value of $593,000 for FY2024, which is 8.49% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Total Non-Current Liabilities stood at $321,000, which was down 22.46% from $414,000 recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $1.0 million for Q2 2022, and its period low was $321,000 during Q3 2025.
  • Its 3-year average for Total Non-Current Liabilities is $599,273, with a median of $595,000 in 2024.
  • Data for Corvus Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY crashed of 48.64% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Total Non-Current Liabilities stood at $985,000 in 2022, then crashed by 34.21% to $648,000 in 2023, then fell by 8.49% to $593,000 in 2024, then crashed by 48.64% to $321,000 in 2025.
  • Its last three reported values are $321,000 in Q3 2025, $414,000 for Q2 2025, and $503,000 during Q1 2025.